---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-23-000055"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:36:23.604829+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q3 net loss $50.5M ($0.21/sh); INPEFA revenue $0.4M since launch

## Summary
- Net loss of $50.5M vs $23.4M a year ago; loss per share $0.21 vs $0.13.
- Total Q3 revenue $0.2M; INPEFA net product revenues since June launch total $0.4M.
- Express Scripts placed INPEFA on Premier Access, Premier Performance (Medicare) and Basic/High Performance (commercial) formularies effective Nov 1.
- LX9211 Phase 2b enrollment expected to begin in December 2023 for diabetic peripheral neuropathic pain.
- Cash and investments $218.4M as of Sept 30, 2023, up from $138.4M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001062822-23-000055
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000055/0001062822-23-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282223000055/lxrx-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-23-000055
- JSON: https://secwatch.observer/filing/0001062822-23-000055.json
- Plain text: https://secwatch.observer/filing/0001062822-23-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.